List view / Grid view
With advancements in artificial intelligence, precision medicine and gene editing, the field of drug discovery is undergoing a rapid transformation. In this article, Drug Target Review’s Izzy Wood gets the insider knowledge from industry leaders at SLAS 2023, who are experiencing these changes first hand.
Japanese scientists have tested the material used to build models of arteries, revealing their suitability for use in medical education and surgical planning.
Tom Darlington, Senior Director at nanoComposix, discusses scaling up manufacturing of nanomaterials for regulated applications and the rewards of working on biomedical projects.
Boosting the body’s anti-viral immune response could restore tissue balance and eliminate ageing cells that contribute to age-related diseases.
New research from Cincinnati Children’s Hospital Medical Center suggests blocking IL-22 and IL-1R could offer a promising IBD treatment.
A newly developed drug displays potential in treating both heart failure and the related sleep apnea.
UCLA have developed technology using nanoparticles that deliver mRNA to liver cells, that could provide a platform to fight allergies.
New findings in mice using artificial sweeteners could result in new therapies to regulate the immune system in those with autoimmune diseases, potentially improving outcomes.
US scientists have developed antibiotics that can “shape-shift”, which prevent bacteria from coming resistant against them.
The researchers identified 1,068 transposable element-derived transcripts with the potential to produce tumour antigens that could serve as targets for new immunotherapies.
US researchers have studied (cannabidiol) CBD as a solution for opioid overdoses, instead of a popular opioid antidote.
4 April 2023 | By GenScript ProBio
The application of Fab and VHH naïve library to expedite the antibody discovery against tumor-associated antigen for CAR-T, ADC and bispecific antibody.
Learning about the mitochondrial role in a neurodegenerative disorder.
Spreading cancer can halt natural pathway that should recruit killer T cells directly to where it has metastasised, US scientists report.
Researchers from the University of Pittsburgh have found that age-associated B cells (ABCs) are key drivers of lupus, a chronic autoimmune disorder that attacks the patient's own organs.
